Metropolitan General Hospital/Healthcare Facilities Operation And Management Single Member S.A
- Address
- lock Available on a paid plan
Targeted KRAS G12C Therapy
Research at Metropolitan General Hospital focuses on KRAS G12C–mutated advanced non‑small cell lung cancer, aiming to evaluate new targeted agents that may improve patient outcomes.
- KRAS G12C inhibition strategies
- Advanced NSCLC patient selection
- Clinical benefit assessment
These studies seek to bring precision medicine options to individuals with limited treatment alternatives.
Immunotherapy Combination Trials
The site conducts trials combining checkpoint inhibitors with chemotherapy in PD‑L1‑positive lung cancer, exploring whether dual approaches can extend progression‑free survival.
- PD‑L1 biomarker-driven enrollment
- Combination of immunotherapy and platinum doublet
- Evaluation of disease control rates
Findings aim to refine treatment sequencing for patients with metastatic disease.
Oncology Research Landscape
At this Greek research center, investigators are advancing cancer care by testing innovative therapies for non‑squamous NSCLC, emphasizing both targeted and immune‑based strategies.
- Integration of molecular profiling
- Multi‑disciplinary trial design
- Collaboration across ten investigators
The ongoing work contributes to the broader European effort to improve outcomes for lung cancer patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 6 therapeutic areas and 15 of 80 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 80 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
- 1Merck Sharp & Dohme LLC4active
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.5trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Metropolitan General Hospital/Healthcare Facilities Operation And Management Single Member S.A
lock Showing 1 of 38 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Open-Label Study Comparing Sigvotatug Vedotin and Docetaxel in Adults with Previously Treated Non-Small Cell Lung Cancer | Seagen Inc. | Phase III | Not Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 80 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 7 | Unknown | 2024-01-23 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.